Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK of IcoSema vs Components in Chinese T2D
NCT05435677Phase 1Completed
- Sponsor
- Novo Nordisk
- Start
- Jun 2022
- Primary completion
- Apr 2023
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of icosema in type 2 diabetes mellitus (T2DM) (6 arms), sponsored by Novo Nordisk. Primary endpoints: Area under the serum insulin icodec concentration-time curve from 0 to last quantifiable concentration at Day 1 and Dose-normalised area under the plasma semaglutide concentration-time curve from 0 to last quantifiable concentration at Day 1. Started Jun 2022; status: completed.
02
Drugs
icosema
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT05435677.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05435677.